tbuckley/cabot-search huggingface dataset:
MEDICINE IN THE CONGO FREE STATE.
Journal: JAMA (1890)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TESTS FOR OCCULT BLOOD.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SOME REFLECTIONS ON HEMIPLEGIA.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Streptobacillary rat-bite fever with massive pericardial effusion
Authors: R. B. Carbeck
Journal: JAMA (1967)

Pericarditis with effusion caused by<i>Streptobacillus moniliformis</i>occurred in a 43-year-old man. Identification of the organism was confirmed by the fluorescent antibody technique. In spite of antibiotic therapy, pericardicentesis, digitalization, and a diuretic regimen, the patient died on the 25th hospital day.
SI Units
Authors: D. W. Fitz-Simons
Journal: JAMA (1979)

<h3>To the Editor.—</h3> As Marvin M. McCall, MD (241:360, 1979), rightly points out, there are still objections to the International System of Units (SI) from physicians in England Four years ago such a debate raged in the correspondence columns of one of the British journals, until details of a tragic accident were published in<i>The Times</i>(Nov 28, 1975, p 6). This incident underlines the need for a cohesive system of units and emphasizes that the benefit accrues not only for scientists and biochemists but for physicians also. The details of the case are simple. A surgeon asked for "normal saline," which the pharmacist understood to mean 1 normal solution of sodium chloride—a chemist's interpretation of the word "normal" being 1 equivalent/L (ie, 54 g/L). The resultant solution was six times too strong and, of course, killed the patient. Had the concentration required been expressed in SI terms of molarity, this
Neurosurgical delivery of the poly ADP ribose polymerase-1 inhibitor olaparib from a thermo-responsive biodegradable paste potentiates radiotherapy and prolongs survival
Authors: Stuart Smith, Riccardo Serra, Jonathan Rowlinson, Noah Gorelick, Gareth Veal, Kevin Shakesheff, Henry Brem, Richard Grundy, Betty Tyler, Ruman Rahman
Journal: Neuro-Oncology (2019)

Abstract There has been considerable interest in repurposing the poly ADP ribose polymerase inhibitor and purported radiosensitiser olaparib (Lynparza), with a recent dose escalation study of olaparib plus temozolomide in recurrent GBM showing good tolerance. Due to systemic therapy-associated caveats such as dose-limiting toxicities and blood-brain-barrier penetration, here we assess localised post-surgical delivery of olaparib from our previously developed PLGA/PEG thermo-sensitive biodegradable paste. Metabolic and clonogenic assays revealed impaired proliferation and clonal growth respectively, upon acute exposure of high-grade glioma cells to olaparib (3–5µM), an effect dramatically potentiated with 3Gy radiation. Flow cytometry of Annexin V+/Propidium iodide+ rodent and human high-grade glioma cells, revealed a significant cell proportion increase at late stage apoptosis when exposed to 2–3µM olaparib and 3Gy radiation (relative to untreated, olaparib alone or radiation alone). A high-grade glioma orthotopic allograft study is ongoing where we already observe a significant overall survival benefit of locally-delivered 10% and 20% w/w (drug:polymer ratio) olaparib via PLGA/PEG paste post-surgery with adjuvant radiotherapy, compared to surgery/oral temozolomide/radiotherapy (GBM standard-of-care) and surgery/systemic olaparib (50 days vs. 44 vs 30 respectively). A more pronounced survival benefit was observed with combined PLGA/PEG/olaparib/temozolomide/radiotherapy or PLGA/PEG/olaparib/etoposide/radiotherapy. RNAseq data from 10 GBM patients show significantly elevated levels of apoptosis-inducing factor-1 in 5-aminolevulinic acid (5ALA)+ fluorescence–activated cell sorted populations (i.e. purified tumour cells from the invasive margin), relative to 5ALA- cells, confirming PARP-1 activity in infiltrative tumour cells. Collectively our data supports a clinical rationale for localised olaparib delivery with adjuvant radiotherapy.
Highlights
Journal: JAMA Cardiology (2018)

Ischemic Heart Disease and Heart Failure Outcomes in VAMCs 563Outcomes of care for patients with ischemic heart disease (IHD) and heart failure (HF) may vary across VA medical centers (VAMCs).Groeneveld and coauthors studied 930 079 patients with IHD and 348 015 with HF among 138 VAMCs and their outpatient clinics between 2010 and 2014.Risk-standardized mortality rates varied from 5.5% to 9.4% for IHD and from 11.1% to 18.9% for HF and significantly exceeded the national means for IHD and HF in 29 and 35 VAMCs, respectively.In an Editorial, Heidenreich discusses the need to address quality measures known to improve mortality to identify interventions that will improve outcomes.
Estrogen Plus Progestin Use Linked With Increased Breast Cancer Incidence and Mortality
Journal: JNCI Journal of the National Cancer Institute (2013)

Cancer Incidence and MortalityEstrogen plus progestin use is linked with increased breast cancer incidence.In addition, prognosis is similar for both users and nonusers of combined hormone therapy, suggesting that mortality from breast cancer may be higher for hormone therapy users as well,
Congenital Syphilis
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CARVACROL IODID.
Authors: ARTHUR H. COHN
Journal: JAMA (1897)

subsequently both confirmed and denied by different writers.Any remedy which is claimed to exert a favorable influence on so grave a malady as carcinoma deserves the most careful and impartial study.Accordingly, in order to repeat these experiments I procured a sample of chelidonium majus and had prepared from it the mixture of extract, distilled water and glycerin recommended.A number of cases of epithelioma were subjected to Denissenko's method, which was faithfully carried out in every particular.A brief account of a few of these may here be given.A lady 63 years of age had noticed a dry, papillary growth upon the lower lip for about two months.The tumor was small in size, dry, wart-like in appear- ance and the seat of occasional stinging pain.There was no ulcération.At times the patient picked at the little tumor and caused the exit of a few drops of blood.
WILLIAM HILLARY (1700-1763)— WEST INDIAN VOYAGER
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Wrong Book Price
Journal: JAMA (1980)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Dear Doctor... Regarding Calcium Channel Blockers-Reply
Authors: E. Paul MacCarthy
Journal: JAMA (1996)

<h3>In Reply.</h3> —Bayer Corporation believes it acted appropriately in the dissemination of the Dear Doctor letter that Dr Stryer and colleagues refer to in their letter. It is our position that the letter by an internationally recognized expert in the treatment of hypertension defending CCBs and nifedipine in particular was a physician-to-physician communication that did not promote, or even mention individual brands, and therefore did not fall under the purview of advertising and labeling regulations. The letter restated this expert's well-known position on the study by Dr Psaty and colleagues<sup>1</sup>and was written by him without any remuneration for his time and effort. In fact, this dialogue
Incorrect Terminology
Authors: Nicholas Stine, Dave Chokshi
Journal: JAMA (2015)

In Reply Dr Zelicoff points to several significant challenges for the development and implementation of successful riskbased quality measures, including limitations of existing risk calculator tools and the ability of clinicians to interpret and communicate statistical risk.We share the sentiment that practical, standardized, and validated approaches to risk calculation and communication are a significant research and educational need.As Zelicoff effectively illustrates with the example of the FRAX tool for osteoporosis, best practice guidelines are imperfectly applied on the ground-perhaps more so when risk calculation is involved.Yet operational challenges should not lead to jettisoning of best practices.Rather, systems and policy solutions to facilitate a higher standard of care should be sought.In this way, we view the application of quality measures as a tool for driving improvement and promoting accountability, rather than merely a common denominator for assessment.Many guidelines are moving in the direction of multifactorial risk assessment, as with the American College of Cardiology/American Heart Association lipid guidelines.Our concern is ensuring that quality measures keep pace with more sophisticated guidelines.Zelicoff's call for particular attention to the integrity of bedside tools and the statistical literacy of clinicians is an important and valuable addition to that conversation.
To treat or not to treat: hyperprolactinemia
Authors: E. R. Gonzalez
Journal: JAMA (1982)

Physicians are overtreating hyperprolactinemia, says Michele C. S. Koppelman, MD, of the National Institute of Child Health and Development (NICHD), Bethesda, Md. At the recent meeting of the Endocrine Society in San Francisco, Koppelman reported on a follow-up study of 25 female patients with long-standing, untreated hyperprolactinemia. Most of the patients' conditions remained stable or improved clinically over the years, and some showed apparent regression of pituitary adenomas. On average, the onset of the patients' symptoms predated the follow-up study by 11.3 years and the diagnoses of hyperprolactinemia by 5.3 years. Half of the women had had initial serum prolactin levels higher than 200 ng/mL, and two thirds had had levels exceeding 100 ng/mL. In 15 patients, skull x-ray films and polytomography of the pituitary fossa had shown abnormalities in the sella turcica. None of the patients with these abnormalities had visual field defects, but several had headaches. At the
Biliary complications in 150 living related liver transplantation (LRLT) Second Department of Surgery, Kyoto University Hospital, Kyoto, Japan
Journal: Hepatology (1995)

It is important to investigate the induction of cytochrome P450 (CYP) enzymes by drugs. The most relevant end point is enzyme activity; however, this requires many cells and is low throughput. We have compared the CYP1A, CYP2B and CYP3A induction response to eight inducers in rat and human hepatocytes using enzyme activities (CYP1A2 (ethoxyresorufin), 2B (benzoxyresorufin for rat and bupropion for human) and CYP3A (testosterone)) and Taqman™ Low Density Array (TLDA) analysis. There was a good correlation between the induction of CYP1A2, CYP2B6 and CYP3A4 enzyme activities and mRNA expression in human hepatocytes. In contrast, BROD activities and mRNA expression in rat hepatocytes correlated poorly. However, bupropion hydroxylation correlated well with Cyp2b1 expression in rat hepatocytes. TLDA analysis of a panel of mRNAs encoding for CYPs, phase 2 enzymes, nuclear receptors and transporters revealed that the main genes induced by the 8 compounds tested were the CYPs. AhR ligands also induced UDP-glucuronosyltransferases and glutathione S-transferases in rat and human hepatocytes. The transporters, MDR1, MDR3 and OATPA were the only transporter genes significantly up-regulated in human hepatocytes. In rat hepatocytes Bsep, Mdr2, Mrp2, Mrp3 and Oatp2 were up-regulated. We could then show a good in vivo:in vitro correlation in the induction response of isolated rat hepatocytes and ex-vivo hepatic microsomes for the drug development candidate, EMD392949. In conclusion, application of TLDA methodology to investigate the potential of compounds to induce enzymes in rat and human hepatocytes increases the throughput and information gained from one assay, without reducing the predictive capacity.
Abstract 322: Discovery of synergistic PI3K inhibitor combination therapies using high throughput approaches in HNSCC
Authors: Nicole Lynn Michmerhuizen, Elizabeth Leonard, Caitlin Heenan, Vivek Nair, Chloe Matovina, Micah Harris, Gabrielle Herbst, Daniel Kim, Amanda Bachand, Jingyi Zhai, Susan K. Foltin, Aditi Kulkarni, Thomas E. Carey, Carol R. Bradford, Hui Jiang, John C. Brenner
Journal: Cancer Research (2019)

Abstract Recent head and neck squamous cell carcinoma (HNSCC) sequencing studies have identified the phosphatidylinositol 3-kinase (PI3K) pathway as the most frequently mutated, oncogenic pathway in this cancer type. Despite frequent activating mutation or amplification in PIK3CA (the gene encoding the catalytic subunit of PI3K), targeted PI3K inhibitors have shown limited clinical efficacy as monotherapies. To identify factors that might predict sensitivity and resistance to PI3K inhibitors, we tested a panel of more than 40 patient-derived HNSCC cell lines and observed varying sensitivity to PI3K inhibitors. While all cell lines were much more sensitive than fibroblasts to these drugs, responses varied widely; for pan-PI3K inhibitor BKM120, IC50 values ranged from 0.2 to 4.2 μM across the OSCC cell line panel. Responses to BKM120 do not correlate with PIK3CA mutation status copy number, RNA expression, p110α protein levels, and AKT phosphorylation at baseline and after inhibitor treatment, among other genetic or phenotypic features. In order to characterize potential mechanisms of PI3K inhibitor resistance in HNSCC, we have also developed and optimized an unbiased, high-throughput screening approach. We have used this assay to test ~1400 inhibitors as monotherapies and in combination with PI3K inhibitors HS-173 and BKM120 in ten HNSCC models. Our initial screening data suggested that combinations of PI3K inhibitors and ALK inhibitors are among the most synergistic in a subset of cell lines. We have evaluated the effects of these drug combinations on apoptosis, cell cycle, and downstream signaling in several in vitro HNSCC models, observing synergy in response to FDA-approved agents PI3K inhibitor pictilisib and ALK inhibitor brigatinib in various systems using a range of techniques. We next plan to expand these analyses to organoid and xenograft models to evaluate their effects in more clinically relevant settings. Future studies will also examine additional factors that may predict PI3K inhibitor responses and will seek to better understand promising combination treatments and advance them for effective use in HNSCC patients. Citation Format: Nicole Lynn Michmerhuizen, Elizabeth Leonard, Caitlin Heenan, Vivek Nair, Chloe Matovina, Micah Harris, Gabrielle Herbst, Daniel Kim, Amanda Bachand, Jingyi Zhai, Susan K. Foltin, Aditi Kulkarni, Thomas E. Carey, Carol R. Bradford, Hui Jiang, John C. Brenner. Discovery of synergistic PI3K inhibitor combination therapies using high throughput approaches in HNSCC [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 322.
RETROPUBIC PROSTATECTOMY
Authors: FRANCIS A. BENEVENTI
Journal: JAMA (1949)

We present an analysis stressing the high lights in successful retropubic prostatectomy in 40 cases done in a city hospital. From this series, in which a large percentage of the patients were poor risks, we were particularly impressed by (a) the smooth convalescence and (b) the appearance of the urethra and bladder neck after operation. <h3>HISTORY</h3> Although the operation has been previously performed in this country<sup>1</sup>and in Europe,<sup>2</sup>it did not capture the fancy of American urologists until after June 1947, when Millin first demonstrated his operation in this country at the Brady Foundation in New York. The feasibility of the operation first became apparent to him during the course of radical cystectomy for carcinoma of the bladder.<sup>3</sup>In removing the bladder transabdominally, he saw no reason why the prostate and seminal vesicles could not be extirpated at the same time without an additional operation via